HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Current Atherosclerosis Reports
C Roger WhiteG M Anantharamaiah

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are currently the drug of choice for the clinical management of elevated low-density lipoprotein (LDL) cholesterol. Although statin treatment provides an overall improvement in outcomes, clinical trial data reveal a significant number of cardiac events despite reaching targeted LDL levels. A low serum high-density lipoprotein (HDL) cholesterol level is an independent predictor of cardiovascular risk. Accordingly, there has been interest in determining whether HDL elevation, in addition to LDL lowering, further reduces risk in patients with coronary artery disease. Several commonly prescribed lipid-lowering therapies modestly raise HDL, but their use may be limited by the development of adverse reactions. Emerging data suggest that HDL quality and function may also be significantly reduced by atherosclerosis and other inflammatory diseases. The goal of this review is to discuss the current status of HDL therapeutics, with emphasis on a novel class of agent, the apolipoprotein A-I mimetic peptides, which improve the functional properties of HDL cholesterol.

References

Jan 1, 1985·Metabolism: Clinical and Experimental·O LeissJ Augustin
May 26, 1970·Biochimica Et Biophysica Acta·R Hirz, A M Scanu
Aug 1, 1981·Archives of Internal Medicine·T GordonT R Dawber
Oct 1, 1994·The Journal of Clinical Investigation·A J MendezJ F Oram
Jan 1, 1994·Advances in Protein Chemistry·J P SegrestG M Anantharamaiah
Apr 1, 1993·Proteins·Y V VenkatachalapathiG M Anantharamaiah
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·D W BorhaniC G Brouillette
Sep 22, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·D T AshbyP J Barter
Oct 28, 1998·Progress in Cardiovascular Diseases·L M Belalcazar, C M Ballantyne
Apr 20, 1999·The Journal of Clinical Investigation·B LamarcheG F Lewis
Jan 19, 2000·Circulation·D J MaronM F Linton
Aug 5, 2000·European Heart Journal·H B RubinsS J Robins
Nov 22, 2001·JAMA : the Journal of the American Medical Association·R ZhangS L Hazen
Jan 19, 2002·Biochemical and Biophysical Research Communications·Michael N OdaTrudy M Forte
Apr 16, 2002·European Journal of Clinical Investigation·B MacknessM I Mackness
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Philip J BarterAlan R Tall
Jun 20, 2003·Current Medical Research and Opinion·A S WierzbickiC B Byrne
Oct 16, 2003·Current Cardiology Reports·Shaista Malik, Moti L Kashyap
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Apr 9, 2004·The New England Journal of Medicine·Margaret E BrousseauDaniel J Rader
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Constanze BergtJay W Heinecke
Sep 2, 2004·Nature Medicine·Alan M Fogelman
Oct 16, 2004·Circulation Research·Philip J BarterAlan M Fogelman
Apr 23, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Mohamad NavabAlan M Fogelman
Jun 18, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Mohamad NavabAlan M Fogelman
Aug 16, 2005·Trends in Cardiovascular Medicine·Mohamad NavabAlan M Fogelman
Dec 24, 2005·Expert Opinion on Investigational Drugs·Srinivasa T ReddyAlan M Fogelman
Feb 3, 2006·Proceedings of the National Academy of Sciences of the United States of America·A Abdul AjeesH M Krishna Murthy

❮ Previous
Next ❯

Citations

Aug 19, 2009·Antioxidants & Redox Signaling·Valery N BochkovJohannes Stöckl
Apr 12, 2014·Bulletin of Mathematical Biology·Anna CohenRosemary S Thompson
Jun 2, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Xiaoyi Hu, Marika Kamberi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.